Results 21 to 30 of about 67,526 (234)

Context, ethics and pharmacogenetics [PDF]

, 2006
Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in ...
Adam M. Hedgecoe, Akhtar, Anderson, Anon, Bazell, Beauchamp, Beeson, Brodaty, Brushwood, Clarke, DeVries, Emery, Ensom, Evans, Farlow, Farrer, Fox, Ginsburg, Haimes, Haseltine, Hedgecoe, Hedgecoe, Hoffmaster, Hoffmaster, Issa, Issa, Jazwinska, Johnson, Kumar, Kumar, Levine, Lindpaintner, Lindpaintner, McConnell, McLeod, Nelson, Noguchi, Nuffield Council on Bioethics., Palmer, Pfost, Poirier, Post, Relkin, Richard, Rioux, Ritchie, Robertson, Roses, Rothstein, Rusnak, Sadee, Saunders, Shi, Smith, Smith, Sugarman, Vaszar, Wolf, Zussman   +58 more
core   +1 more source

Cancer Pharmacogenomics [PDF]

Clinical Pharmacology & Therapeutics, 2011
Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of ...
S. W. Paugh, STOCCO, GABRIELE, J. R. McCorkle, B. Diouf, K. R. Crews, W. E. Evans   +5 more
openaire   +3 more sources

DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion. [PDF]

, 2017
INTRODUCTION:The perioperative pain experience shows great interindividual variability and is difficult to predict. The mu-1 opioid receptor gene (OPRM1) is known to play an important role in opioid-pain pathways.
Chidambaran, Vidya, Ding, Lili, Geisler, Kristie, Ji, Hong, Martin, Lisa J, Sadhasivam, Senthilkumar, Stubbeman, Bobbie L, Weirauch, Matthew T, Zhang, Xue   +8 more
core   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

Physicians’ pharmacogenomics information needs and seeking behavior: a study with case vignettes

BMC Medical Informatics and Decision Making, 2017
Background Genetic testing, especially in pharmacogenomics, can have a major impact on patient care. However, most physicians do not feel that they have sufficient knowledge to apply pharmacogenomics to patient care. Online information resources can help
Bret S. E. Heale, Aly Khalifa, Bryan L. Stone, Scott Nelson, Guilherme Del Fiol   +4 more
doaj   +1 more source

Pharmacogenomics in children: advantages and challenges of next generation sequencing applications [PDF]

, 2013
Pharmacogenetics is considered as a prime example of how personalized medicine nowadays can be put into practice. However, genotyping to guide pharmacological treatment is relatively uncommon in the routine clinical practice. Several reasons can be found
De Paepe, Anne, Vanakker, Olivier
core   +4 more sources

Irinotecan Pharmacogenomics

Pharmacogenomics, 2010
Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment. Although multiple genes may play a role in irinotecan activity, the majority of evidence to date suggests that variation in expression of UGT1A1 caused by a common promoter polymorphism (UGT1A1*28) is ...
Sharon, Marsh, Janelle M, Hoskins
openaire   +3 more sources

Genetic and Modifiable Risk Factors Contributing to Cisplatin-Induced Toxicities [PDF]

, 2019
Effective administration of traditional cytotoxic chemotherapy is often limited by off-target toxicities. This clinical dilemma is epitomized by cisplatin, a platinating agent that has potent antineoplastic activity due to its affinity for DNA and other ...
Dinh, Paul C. Jr., Dolan, M., El Charif, Omar, Travis, Lois B., Trendowski, Matthew R.   +4 more
core   +1 more source

Cardiovascular pharmacogenomics

Experimental Physiology, 2005
There is large interpatient variability in the response to drugs, including cardiovascular drugs. Thus, while some patients achieve the desired therapeutic response from their drug therapy, others do not. There is also a subset of patients who will experience adverse effects, which can range from bothersome to life threatening. Research in recent years
Julie A, Johnson, Larisa H, Cavallari
openaire   +2 more sources

Genetics and Genomics in Sickle Cell Disease in Africa. [PDF]

Am J Hematol
ABSTRACT Advanced genomic technologies are revolutionizing our ability to understand complex diseases. Large‐scale population studies are needed to realize the potential of using individual genetic information to personalize treatments for better patient outcomes for chronic non‐communicable diseases, such as sickle cell disease (SCD).
Nkya S, Makani J, Flanagan JM.
europepmc   +2 more sources